Dr. Cecil B. Pickett joins the GVK Biosciences Scientific Advisory Board
GVK Biosciences (GVK BIO) announced the appointment of Dr. Cecil B. Pickett as Scientific Advisor to the Board of Directors.

Cecil B. Pickett, Ph.D.
GVK Biosciences
Cecil B. Pickett, Ph.D. has served as President of Research and Development, and member of the Biogen Idec Board of Directors for three years (March 2006-October 2009). Prior to joining Biogen Idec, Dr. Pickett held several senior R&D positions at Schering-Plough Corporation. As the Senior Vice President & President, Schering-Plough Research Institute, Dr. Pickett helped bring several large and small molecule candidates into the Schering-Plough clinical development pipeline. Prior to joining Schering-Plough, he held several senior R&D positions at Merck & Company.
Dr. Pickett received his B.S. in Biology from California State University, Hayward, Calif., and his Ph.D. in Cell Biology from the University of California, Los Angeles (UCLA).
Dr. Pickett has served as a member of the U.S. Food and Drug Administration (FDA) Science Board, the Advisory Committee to the Director of the National Institutes of Health and The National Cancer Policy Board of the Institute of Medicine. He has served as a member of the National Academies Committee on Science, Engineering and Public Policy and a member of the Institute of Medicine Forum on Drug Discovery, Development and Translation. He also sits on the Board of Directors with Zimmer Holdings Inc, was elected to the Institute of Medicine of the National Academy of Sciences in 1993 and also is a member of The American Society for Cell Biology, American Society of Biochemistry & Molecular Biology, American Association for Cancer Research, and the American Association for the Advancement of Science.
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Photocure’s Cevira shows positive interim results for treatment of precancerous lesions of the cervix - Six-month interim data presented at international conference addressing prevention of cervical cancer
Horizon Discovery Announces Strategic Partnership with Promega to Develop Next-Generation Predictive Human Disease Models

Triple-threat cancer-fighting polymer capsules for guided drug delivery created
New prostate cancer treatment may be riskier
Genzyme and Bayer HealthCare Enter New Strategic Agreement - Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis

Billion-euro takeover: Roche joins the fight against obesity
Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
Immune system reveals new ways to treat brain disease and pain
Genomatix partners with Research Instruments Pte Ltd for Singapore, Malaysia and Thailand markets

The 2013 Nobel Prize in Physiology or Medicine: Machinery regulating vesicle traffic
